In The Media

From The media

OCON Therapeutics has reached its recruitment goal of its Phase IIb clinical study evaluating the revolutionary IUB® SEAD®, a non-invasive treatment for heavy menstrual bleeding affecting 1 in 3 women

March 24, 2023



OCON Therapeutics is honored to be part of Bolt PR’s (A Millwright Agency) important list of Femtech Brands and Innovations to watch in 2023

March 15, 2023



OCON Therapeutics participating in the World Economic Forum’s Industry Strategy Meeting in Geneva as Technology Pioneer

March 14, 2023



OCON Therapeutics’s CEO, Keren Leshem, recognized as 1 in 10 Israeli women to watch in 2023

March 10, 2023